Clik here to view.
#ASCO24: With a promising new Keytruda contender, Summit prepares to spar...
CHICAGO — Summit Therapeutics is prepared to take on the world’s best-selling drug. On Thursday, the biotech’s stock nearly tripled after reporting that its cancer drug ivonescimab beat Merck’s...
View ArticleClik here to view.
#ASCO24: A small group of melanoma patients may need far less immunotherapy...
Interim results from a clinical trial conducted by researchers in the Netherlands and Australia suggest that some melanoma patients may need far less immunotherapy than they’re currently prescribed....
View ArticleIsotope shortage forces pause of Bristol Myers Phase 3 radiopharmaceutical trial
The development of the lead drug behind Bristol Myers Squibb’s recent $4.1 billion acquisition of RayzeBio has hit delays, because of supply issues of a rare radioactive isotope crucial to the...
View ArticleEli Lilly licenses preclinical antisense program designed to treat ALS, dementia
Eli Lilly added another neuroscience program to its pipeline, licensing an antisense oligonucleotide from the ALS biotech QurAlis. The deal, announced Monday, is the latest indicator that Lilly is...
View ArticleClik here to view.
Rapport Therapeutics sets out for $122M Nasdaq debut as IPO backlog seeks...
Clinical-stage neuroscience biotech Rapport Therapeutics will seek about $122 million in net proceeds from its initial public offering, according to new securities paperwork outlining its Nasdaq...
View ArticleDelaware court lets Zantac lawsuits go ahead, wiping $8B+ from GSK market cap
GSK shares were down more than 9% premarket on Monday after a Delaware court allowed more than 70,000 Zantac-related cases against the drugmaker to go ahead. Judge Vivian Medinilla concluded on Friday...
View Article#ASCO24: Caribou says partial HLA matching will improve durability of...
CHICAGO — Caribou’s off-the-shelf cell therapy appears poised to break free from the rapid relapses that have plagued other off-the-shelf cell therapies, according to a retrospective analysis, but the...
View ArticleClik here to view.
Takeda outlines mid-stage narcolepsy data that prompted 'rapid' move into...
Takeda presented fleshed-out Phase 2b data for a narcolepsy drug touted by its CEO and reiterated plans to launch Phase 3 trials by September. Elena Koundourakis The drug, called TAK-861, was tested at...
View ArticleArrowhead targets rare genetic disorder filing for RNAi after Phase 3 win
Arrowhead Pharmaceuticals’ RNAi treatment has succeeded in a registrational test in patients with an ultra-rare lipid metabolism disorder, bolstering plans for a regulatory filing that follows hot on...
View ArticleStructure's oral GLP-1 produces comparable weight loss to Lilly's oral candidate
Structure Therapeutics’ oral GLP-1 hit all endpoints in a pair of mid-stage studies evaluating weight loss and safety, sending its stock $GPCR up nearly 55% on Monday morning. The drug, dubbed...
View ArticleAgios plans thalassemia filing in US after unveiling data in...
Agios Pharmaceuticals’ stock $AGIO jumped more than 19% on Monday morning after the company announced its oral candidate for the blood disorder thalassemia reduced patients’ need for transfusions in a...
View ArticleFauci pushes back on pandemic criticisms before divided House panel
Four years after the Covid-19 pandemic began, the nation’s former top infectious disease official Anthony Fauci appeared on Monday before a panel of lawmakers to defend his response to the pandemic....
View ArticleClik here to view.
At ASCO: big readouts, revenue questions, and the ups and downs of ADCs
CHICAGO – More than 40,000 clinicians, biopharma executives, investors, drug salespeople and many others involved in cancer research descended upon McCormick Place in Chicago for the American Society...
View ArticleHow FarmboxRx uses food deliveries to encourage patients to get preventive care
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) FarmboxRx is putting a spin on the usual food-as-medicine programs. The startup, founded in 2014,...
View Article#ASCO24: Sanofi touts Phase 3 Sarclisa data in multiple myeloma as it plays...
Sanofi reported positive Sarclisa data from a registrational test in certain newly-diagnosed multiple myeloma patients, with the company anticipating a US launch as early as this year. The French...
View ArticleIllumina board agrees to spin off Grail rather than sell the cancer...
Illumina’s board has decided to spin out Grail into its own company this month, the DNA sequencing company announced Monday. Since Illumina announced in December that it would unwind its $8 billion...
View ArticleClik here to view.
Australian life sciences VC Brandon Capital raises $180M for sixth fund
Melbourne-based Brandon Capital has secured AUD $270 million ($180 million) to continue seeding life sciences companies in its home country of Australia and New Zealand, and extend its presence into...
View ArticleClik here to view.
Merck KGaA continues AI drug discovery deal spree with Biolojic Design
Merck KGaA has tapped Israel biotech Biolojic Design to help create multi-specific antibodies using AI. In the latest AI-driven collaboration Merck KGaA has announced in the past several months,...
View ArticleStartup raises $25M for cancer drug targets created by alternative RNA splicing
Envisagenics, a startup founded by scientists from Cold Spring Harbor Laboratory, has raised a $25 million series B round to develop drugs for cancer and neurodegenerative disease, the company told...
View ArticleAnnexon proclaims Phase 3 win for complement inhibitor in Guillain-Barré...
Annexon Biosciences reported new Phase 3 data for its Guillain-Barré Syndrome (GBS) drug Tuesday morning, saying the low dose achieved the trial’s primary endpoint. The company has a lot riding on the...
View Article